AM-x Synthetic Cannabinoids Research Dashboard
Clinical Studies
0
Double-blind human trials
0
Clinical human trials
Pre-Clinical Studies
69
Animal studies
17
Laboratory studies
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 162 studies associated with AM-x Synthetic Cannabinoids.
Here is a small sampling of AM-x Synthetic Cannabinoids studies by title:
- CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell function
- Comparison of the Neurotoxic and Seizure-Inducing Effects of Synthetic and Endogenous Cannabinoids with Δ 9-Tetrahydrocannabinol
- CB2R orchestrates neuronal autophagy through regulation of the mTOR signaling pathway in the hippocampus of developing rats with status epilepticus
- A new target to ameliorate the damage of periodontal disease: The role of transient receptor potential vanilloid type-1 in contrast to that of specific cannabinoid receptors in rats
- Cannabinoid 2 Receptor-Based Modulation of the Immune Response in Experimental Models of CNS Injury
Components of the AM-x Synthetic Cannabinoids Research Dashboard
- Top medical conditions associated with AM-x Synthetic Cannabinoids
- Proven effects in clinical trials for AM-x Synthetic Cannabinoids
- Receptors associated with AM-x Synthetic Cannabinoids
- Individual study details for AM-x Synthetic Cannabinoids
Ready to become a subscriber? Go to our PRICING page.
Filter Cannabinoid
Members can filter by the following criteria:
- Study Type
- Organ Systems
- Terpenes
- Receptors
- Ligands
- Study Result
- Year of Publication
Overview - AM-x Synthetic Cannabinoids
Description of AM-x Synthetic Cannabinoids
The AM class of synthetic cannabinoids are named after their producer, Alexandros Makriyannis, a professor at Northeastern University in Boston. This class of cannabinoids can produce a variety of different effects. A prominent example is AM-251.
Other Names:
AM Family Synthetic Cannabinoids
AM-x Synthetic Cannabinoids Properties and Effects
May have apoptotic properties in human cutaneous melanoma.
AM-x Synthetic Cannabinoids Receptor Binding
Full antagonist and strong affinity at CB1 (Ki 7.5nM). Weak affinity and agonist at GPR-55. μ-opioid receptor antagonist (Ki = 251 nM)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.